Stephan Duparc in Proceedings of International Conference on Plasmodium vivax

Papers 3

Safety of primaquine as an antirelapse agent: Data from India
Achieving Universal access to safe and radical cure

Anupkumar Rameshrao Anvikar ¹ ; Stephan Duparc ² ; Madan Pradhan ³ ; Prajyoti Sahu ³ ; Sreya Kumbhakar ³ ; Kamini Mendis ¹ ; Jaya Banerji ² ; Penny Grewal ² ; Neena Valecha ¹

¹ National Institute of Malaria Research, New Delhi, India. ;

² MMV Geneva, Switzerland. ;

³ National Vector Borne Diseases Control Programme Odisha, India.

Vol.1, 2017 -
63801
Tafenoquine for radical cure of Plasmodium vivax malaria: a randomized, double-blind, double-dummy, comparative, multicenter Phase III study (“GATHER”).
Achieving Universal access to safe and radical cure

Marcus Vinícius Guimarães de Lacerda ¹ ; Elmer Llanos-Cuentas ² ; Cindy Chu ³ ; Tran T. Hien ⁴ ; Chaiado Namaik-Larp ⁵ ; Maria F. Villegas ⁶ ; Ivan D. Velez ⁷ ; Stephan Duparc ⁸ ; Sion W. Jones ⁹ ; Elizabeth Hardaker ⁹ ; Khadeeja Mohamed ⁹ ; Gavin CKW Koh ⁹ ; Jutin A Green ⁹ ; Viviana Wilches ¹⁰ ; John Breton ¹⁰

¹ Fundação de Medicina Tropical do Amazonas, Brazil ;

² Universidad Peruana Cayetano Heredia, Lima, Peru ;

³ Shoklo Malaria Research Unit, Thailand ;

⁴ Oxford University Clinical Research Unit, Vietnam ;

⁵ Umphang Hospital, Thailand ;

⁶ Centro de investigaciones Clinicas SAS, Colombia ;

⁷ PECET, Universidad de Antioquia, Medellin, Colombia ;

⁸ Medicines for Malaria Venture, Switzerland ;

⁹ GlaxoSmithKline, United Kingdom ;

¹⁰ GlaxoSmithKline, USA

Vol.1, 2017 -
63245
Tafenoquine for radical cure of Plasmodium vivax malaria: a multicentre, randomised, double-blind, placebo-controlled phase III trial (“DETECTIVE”).
Achieving Universal access to safe and radical cure

Elmer Llanos-Cuentas ¹ ; Marcus Vinícius Guimarães de Lacerda ² ; Raul Chuquiyauri ¹ ; David Saunders ³ ; Lon Chanthap ³ ; Daniel Yilma ⁴ ; Rezika Mohammed ⁵ ; Srivicha Krudsood ⁶ ; Dhelio Pereira ⁷ ; Fe Espino ⁸ ; Harald Noedl ⁹ ; Brian Angus ¹⁰ ; Joerg-Peter Kleim ¹¹ ; Stephan Duparc ¹² ; Sion W. Jones ¹¹ ; Elizabeth Hardaker ¹¹ ; Khadeeja Mohamed ¹¹ ; Kim Fletcher ¹¹ ; Jhon Breton ¹³ ; Jutin A Green ¹¹ ; Cletus O. Ugwuegbulam ¹¹ ; Gavin CKW Koh ¹¹

¹ Universidad Peruana Cayetano Heredia, Lima, Peru ;

² Instituto Leonidas e Maria Deane, Fiocruz, Manaus, Brazil ;

³ Armed Forces Research Institute of Medical Sciences, Thailand ;

⁴ Jimma University, Ethiopia ;

⁵ University of Gondar, Ethiopia ;

⁶ Mahidol University, Thailand ;

⁷ Centro de Pesquisa em Medicina Tropical de Rondonia, Brazil ;

⁸ Research Institute for Tropical Medicine, Philippines ;

⁹ University of Vienna, Austria ;

¹⁰ University of Oxford, United Kingdom ;

¹¹ GlaxoSmithKline, United Kingdom ;

¹² Medicines for Malaria Venture, Switzerland ;

¹³ GlaxoSmithKline, USA

Vol.1, 2017 -
63246

Proceedings of International Conference on Plasmodium vivax

Stephan Duparc

Safety of primaquine as an antirelapse agent: Data from India

Tafenoquine for radical cure of Plasmodium vivax malaria: a randomized, double-blind, double-dummy, comparative, multicenter Phase III study (“GATHER”).

Tafenoquine for radical cure of Plasmodium vivax malaria: a multicentre, randomised, double-blind, placebo-controlled phase III trial (“DETECTIVE”).

Co-authors (36)

Marcus Vinícius Guimarães de Lacerda

Elmer Llanos-Cuentas

Elizabeth Hardaker

David Saunders

Jutin A Green

Gavin CKW Koh

Khadeeja Mohamed

Neena Valecha

Sion W. Jones

Brian Angus

Penny Grewal

Jaya Banerji

Kamini Mendis

Sreya Kumbhakar

Prajyoti Sahu

Madan Pradhan

Anupkumar Rameshrao Anvikar

Cletus O. Ugwuegbulam

Jhon Breton

Kim Fletcher

Joerg-Peter Kleim

Harald Noedl

Ivan D. Velez

Fe Espino

Dhelio Pereira

Srivicha Krudsood

Cindy Chu

Daniel Yilma

Lon Chanthap

Tran T. Hien

Raul Chuquiyauri

John Breton

Viviana Wilches

Chaiado Namaik-Larp

Maria F. Villegas

Rezika Mohammed